Lung Cancer Associated With Cystic AirspacesNCT07066813
Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
An observational study of Lung Cancer Associated With Cystic Airspaces, run by Central South University at 1 site in China.
Trial summary
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Lung Cancer Associated With Cystic Airspaces
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2025to 1 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with LCCA who underwent surgical treatment in the Second Xiangya Hospital of Central South University
Who may be able to join
- Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
- Patients who have undergone surgical lung resection;
- Patients with complete preoperative chest CT imaging data;
- Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.
Who cannot join
- History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis [LAM], or Birt-Hogg-Dubé [BHD] syndrome);
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Patients with concurrent other malignancies;
- Patients with missing or poor-quality preoperative chest CT imaging data.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011
Ping Jiang, 0731-85292476, xy2gcpjiang@163.com
About this study
Official title: T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:
- What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?
- How do imaging features of cystic lesions correlate with their pathological characteristics?
- What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?
- Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| group 1 | radiologic T stage based on the maximum tumor diameter including cystic components | |
| group 2 | radiologic T stage based on the diameter of the solid/invasive portion only | |
| group 3 | pathologic T stage derived from the resected specimen |
What is being measured
The primary outcome is the main question the study is designed to answer.
DFS
Disease-Free Survival
Measured: From enrollment to the end of surgery for 5 years
OS
Overall Survival
Measured: From enrollment to the end of surgery for 5 years
Secondary outcomes (5)
Rate of T-stage reclassification
T-stage reclassification
Measured: From enrollment to the end of surgery for 5 years
AI-based extraction of radiologic characteristics of cystic airspace-associated lesions
Machine learning was employed to extract and analyze the radiologic characteristics of cystic airspace-associated lesions.
Measured: From enrollment to the end of surgery for 5 years
AI to extract and analyze pathological features
Machine learning was employed to extract and analyze pathological features
Measured: From enrollment to the end of surgery for 5 years
Oncogenic driver genetic alterations
Results of driver gene mutation testing
Measured: From enrollment to the end of surgery for 5 years
Receipt of postoperative adjuvant therapy
Postoperative adjuvant therapy was ascertained from medical records
Measured: From enrollment to the end of surgery for 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2025
- Study start1 Jun 2025
- Primary completion31 Oct 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer Associated With Cystic AirspacesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central South University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chen Chen, Second Xiangya Hospital of Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07066813
- Sponsor's protocol ID
- LYEC2025-K0017
- Status last verified
- Sep 2026
- First submitted
- 5 Jul 2025
- Last updated
- 4 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07066813
- Acronym / sponsor ID
- LYEC2025-K0017
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Central South UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 15 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:
- What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?
- How do imaging features of cystic lesions correlate with their pathological characteristics?
- What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?
- Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| group 1 | – | –radiologic T stage based on the maximum tumor diameter including cystic components |
| group 2 | – | –radiologic T stage based on the diameter of the solid/invasive portion only |
| group 3 | – | –pathologic T stage derived from the resected specimen |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with LCCA who underwent surgical treatment in the Second Xiangya Hospital of Central South University
Key inclusion criteria (4 listed)
- Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
- Patients who have undergone surgical lung resection;
- Patients with complete preoperative chest CT imaging data;
- Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.
Key exclusion criteria (4 listed)
- History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis [LAM], or Birt-Hogg-Dubé [BHD] syndrome);
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Patients with concurrent other malignancies;
- Patients with missing or poor-quality preoperative chest CT imaging data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
DFS
Time frame: From enrollment to the end of surgery for 5 years
Disease-Free Survival
OS
Time frame: From enrollment to the end of surgery for 5 years
Overall Survival
5 secondary outcomes
Rate of T-stage reclassification
Time frame: From enrollment to the end of surgery for 5 years
AI-based extraction of radiologic characteristics of cystic airspace-associated lesions
Time frame: From enrollment to the end of surgery for 5 years
AI to extract and analyze pathological features
Time frame: From enrollment to the end of surgery for 5 years
Oncogenic driver genetic alterations
Time frame: From enrollment to the end of surgery for 5 years
Receipt of postoperative adjuvant therapy
Time frame: From enrollment to the end of surgery for 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer Associated With Cystic Airspaces
RecruitingObservational study
Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
Lung Cancer Associated With Cystic Airspaces
RecruitingObservational study
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer Associated With Cystic Airspaces, run by Central South University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chen Chen (+8673185295188, chenchen1981412@csu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DFS (time frame: From enrollment to the end of surgery for 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.